Jaguar Health (JAGX) Earns Coverage Optimism Score of 0.39

Media stories about Jaguar Health (NASDAQ:JAGX) have been trending positive this week, according to Accern Sentiment Analysis. The research group identifies positive and negative news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Jaguar Health earned a media sentiment score of 0.39 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 48.5120030369043 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

These are some of the media stories that may have impacted Accern’s scoring:

How to Become a New Pot Stock Millionaire

Separately, ValuEngine upgraded shares of Jaguar Health from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd.

JAGX remained flat at $$0.18 on Friday. 1,648,067 shares of the company were exchanged, compared to its average volume of 10,976,428. The company has a current ratio of 0.26, a quick ratio of 0.15 and a debt-to-equity ratio of 0.35. Jaguar Health has a 52-week low of $0.10 and a 52-week high of $0.99.

TRADEMARK VIOLATION NOTICE: This news story was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another site, it was copied illegally and reposted in violation of United States & international copyright & trademark legislation. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2018/04/07/jaguar-health-jagx-getting-favorable-media-coverage-study-finds.html.

Jaguar Health Company Profile

Jaguar Health, Inc, formerly Jaguar Animal Health, Inc, is a natural-products pharmaceuticals company. The Company is focused on developing and commercializing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis. The Company, through its subsidiary Napo Pharmaceuticals, Inc, is focused on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas.

Insider Buying and Selling by Quarter for Jaguar Health (NASDAQ:JAGX)

Receive News & Ratings for Jaguar Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jaguar Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply